Dr. Lalchandani Labs Ltd.

As of March 31, 2026, Dr. Lalchandani Labs Ltd. carries a market capitalization of 127.91M, placing it among publicly traded companies globally. Its enterprise value stands at 107.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Dr. Lalchandani Labs Ltd. has 8.64M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Dr. Lalchandani Labs Ltd. maintains a current ratio of 3.79, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

As of the close on October 21, 2026, Dr. Lalchandani Labs Ltd.'s stock has declined approximately 58.98% over the past 52 weeks. The 50-day moving average sits at 7.33, while the 200-day moving average is 11.14.

As of March 31, 2026, Dr. Lalchandani Labs Ltd. holds 41.41M in cash and equivalents against 20.64M in total debt, resulting in a net debt position of -20.77M. Total book value stands at 141.33M, with working capital of 94.34M providing operational flexibility.

Dr. Lalchandani Labs Ltd.'s most recent stock split took place on January 27, 2026 with a 309:418 split ratio.